Infants exposed in utero to antiepileptic drugs. A prospective study.
D000014:Abnormalities, Drug-Induced; D000293:Adolescent; D000328:Adult; D000639:Amitriptyline / Q000009:adverse effects; D000653:Amniotic Fluid / Q000032:analysis; D000927:Anticonvulsants / Q000009:adverse effects*; D002849:Chromatography, Gas; D003975:Diazepam / Q000009:adverse effects; D004827:Epilepsy / Q000188:drug therapy*; D005013:Ethosuximide / Q000009:adverse effects; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006130:Growth Disorders / Q000139:chemically induced*; D006801:Humans; D006827:Hydantoins / Q000009:adverse effects; D007231:Infant, Newborn; D013058:Mass Spectrometry; D008618:Mephobarbital / Q000009:adverse effects; D008620:Meprobamate / Q000009:adverse effects; D008895:Milk, Human / Q000032:analysis; D010634:Phenobarbital / Q000009:adverse effects / Q000097:blood / Q000652:urine; D010672:Phenytoin / Q000009:adverse effects / Q000097:blood / Q000652:urine; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011324:Primidone / Q000009:adverse effects; D011346:Prochlorperazine / Q000009:adverse effects; D011446:Prospective Studies; D013375:Substance Withdrawal Syndrome; D013388:Succinimides / Q000009:adverse effects; D013997:Time Factors
D000927:Anticonvulsants; D006827:Hydantoins; D013388:Succinimides; D011324:Primidone; D000639:Amitriptyline; D008618:Mephobarbital; D005013:Ethosuximide; D010672:Phenytoin; D008620:Meprobamate; D003975:Diazepam; D011346:Prochlorperazine; D010634:Phenobarbital